跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 63 条关于
“FYB203/AHZANTIVE”
全部
63
临床试验
16
药物
3
机构
0
资讯
44
去年
Formycon's Aflibercept Biosimilar FYB203 Receives Positive CHMP Opinion for EU Approval
去年
Formycon's Aflibercept Biosimilar FYB203 Receives Positive CHMP Opinion for EU Approval
2年前
FDA Approves Ahzantive, a Biosimilar to Eylea, for Retinal Diseases
去年
Valorum Biologics Secures Exclusive Rights to Commercialize Formycon's Eylea Biosimilar in North America
去年
Formycon's Aflibercept Biosimilar, AHZANTIVE®/Baiama®, Receives Positive CHMP Opinion for EU Approval
去年
Formycon Expands Global Reach for Eylea Biosimilar Through Strategic Partnerships with Teva and Lotus Pharmaceutical
去年
Formycon's Aflibercept Biosimilar (FYB203) Gains EU Approval for Retinal Diseases
去年
CHMP Issues Positive Opinion for Formycon's Aflibercept Biosimilar FYB203
去年
CHMP Recommends Aflibercept Biosimilar FYB203 for Retinal Diseases
去年
CHMP Issues Positive Opinion for Aflibercept Biosimilar FYB203
第 1 页,共 5 页
上一页
下一页